Aripiprazole
| Status | Commercial |
| Development phase | |
| Therapeutic cat. | Neurology |
| Polymorphic form | Type I |
| CAS No. | 129722-12-9 |
| Reference Product | |
| Injectable Form | Injectable |
| EU DMF readiness |  |
| CEP | |
| CHINESE DMF | |
| JAPANESE DMF | |
| KOREAN DMF | |
| CANADIAN DMF | |
| CADIFA | |
| US DMF readiness | |
| OEB No. | |
| Samples |
Drug description
Aripiprazole is an antipsychotic medicine that is used to treat schizophrenia in adults and children at least 13 years old. Aripiprazole is also used in children 6 years or older who have Tourette's disorder, or symptoms of autistic disorder (irritability, aggression, mood swings, temper tantrums, and self-injury). Aripiprazole is used alone or with a mood stabilizer medicine to treat bipolar I disorder (manic depression) in adults and children at least 10 years old. Aripiprazole is used with antidepressant medication to treat major depressive disorder in adults.
Polpharma API
- Long experience in in-house commercial manufacturing
- 2 production lines
- Injection grade anhydrous API
Disclaimer
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).
